AGN - Allergan plc

NYSE - Nasdaq Real Time Price. Currency in USD
184.08
-0.38 (-0.21%)
As of 2:52PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close184.46
Open184.00
Bid184.05 x 900
Ask184.15 x 800
Day's Range183.27 - 185.04
52 Week Range142.81 - 237.41
Volume2,296,807
Avg. Volume2,078,929
Market Cap62.485B
Beta1.25
PE Ratio (TTM)N/A
EPS (TTM)-6.30
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & Yield2.88 (1.71%)
Ex-Dividend Date2018-05-17
1y Target Est208.45
Trade prices are not sourced from all markets
  • A Financial Overview of Bausch Health Companies in August
    Market Realist3 hours ago

    A Financial Overview of Bausch Health Companies in August

    In the first half of 2018, Bausch Health reported revenue of $4.1 billion compared to $4.3 billion in the same period last year. Bausch Health reported net income of -$873 million in the second quarter compared to -$38 million in the same period last year. In the first half of 2018, Bausch Health reported net income of -$3.45 billion compared to -$590 million in the same period last year.

  • 3 Stocks for Warren Buffett Fans
    Motley Fool4 hours ago

    3 Stocks for Warren Buffett Fans

    If you like the Oracle's style, these stocks are for you.

  • How Analysts View Bausch Health Companies in August
    Market Realist5 hours ago

    How Analysts View Bausch Health Companies in August

    After the first half of 2018, Bausch raised its full-year adjusted EBITDA guidance from $3.15 billion–$3.30 billion to $3.20 billion–$3.35 billion. In August, Bausch Health’s wholly owned subsidiary Salix Pharmaceuticals and US WorldMeds announced the launch of Lucemyra 0.18 mg tablets in the US market. Right now, Lucemyra is the first and only non-opioid drug indicated for the mitigation of opioid withdrawal symptoms for facilitating rapid opioid discontinuation in adults.

  • Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
    Zacksyesterday

    Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

    Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.

  • Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why
    Zacksyesterday

    Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why

    Allergan (AGN) is having a relatively better 2018 with the stock on an upward trajectory since announcement of earnings in July. Let us have a look at the reasons for the same.

  • The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

  • Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
    Zacks5 days ago

    Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

    Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

  • Editas Prepares for the Commercialization of EDIT-101
    Motley Fool6 days ago

    Editas Prepares for the Commercialization of EDIT-101

    The genome-editing specialist just offered its latest update on the state of the business. Here's what investors need to know.

  • What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
    Market Realist7 days ago

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.

  • Editas Medicine (EDIT) Q2 2018 Earnings Conference Call Transcript
    Motley Fool7 days ago

    Editas Medicine (EDIT) Q2 2018 Earnings Conference Call Transcript

    EDIT earnings call for the period ending June 30, 2018.

  • PR Newswire7 days ago

    Allergan Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process

    DUBLIN, Aug. 8, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced that Michael E. Greenberg, PhD will join its Board of Directors effective immediately, as part of the company's ongoing board refreshment process. Dr. Greenberg is the Nathan Marsh Pusey Professor of Neurobiology at Harvard University and the Co-Lead of the Allen Discovery Center for Human Brain Evolution at Harvard Medical School.

  • Bausch Health Companies Stock Rose ~8% after Q2 Results
    Market Realist8 days ago

    Bausch Health Companies Stock Rose ~8% after Q2 Results

    Bausch Health Companies stock was trading at $24.39 today, an ~8.40% increase from yesterday’s close of $22.50. On August 6, Bausch Health stock closed at $22.50, which represents a ~106% increase from its 52-week low of $10.94 on November 2, 2017. After Q2 2018 financial results, Bausch Health Companies raised its full-year adjusted EBITDA guidance from $3.15 billion–$3.30 billion to $3.20 billion–$3.35 billion. Bausch Health anticipates net revenues for the fiscal year 2018 to be in the range of $8.15 billion and $8.35 billion. 

  • Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down
    Zacks8 days ago

    Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down

    Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.

  • PR Newswire9 days ago

    Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

    DUBLIN and CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.

  • GlobeNewswire9 days ago

    Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

    Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.

  • Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down
    Zacks12 days ago

    Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down

    Teva's (TEVA) shares dip on mixed second-quarter results. The company maintains its 2018 sales guidance while raising the earnings outlook.

  • Eli Lilly’s Q2 2018 Earnings: Elanco
    Market Realist12 days ago

    Eli Lilly’s Q2 2018 Earnings: Elanco

    Elanco is Eli Lilly & Co.’s (LLY) animal health business. Elanco reported revenues of $792.1 million in the second quarter, representing 1.0% YoY (year-over-year) growth from $784.8 million in the second quarter of 2017. The chart below shows Elanco’s revenues since the first quarter of 2017.

  • Reuters12 days ago

    Spain's Almirall bets on dermatology with $650 mln U.S. deal

    Spanish pharmaceutical company Almirall said on Friday it had agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash. The deal will make dermatology into Almirall's main growth driver, increasing the business's net sales to nearly 45 percent of the group total from 34 percent, Almirall said. "This is a transformational deal for Almirall.

  • Reuters12 days ago

    Spain's Almirall to buy U.S. dermatology portfolio from Allergan

    Spanish pharmaceutical company Almirall SA said on Friday it has agreed to buy a portfolio of five brands from U.S. firm Allergan for up to $650 million in cash. Almirall said it would pay $550 million ...

  • Allergan sues Pfizer over costs of opioid litigation
    Reuters13 days ago

    Allergan sues Pfizer over costs of opioid litigation

    In a lawsuit filed in federal court in Cleveland, Ohio, Allergan said the "primary basis" for the claims against it was the alleged improper marketing and sale of Kadian, a form of morphine, in the years before it gained rights to the painkiller in late 2008. "But now that more than a thousand lawsuits seek to impose liability for that very marketing and sale, Pfizer has rejected any responsibility to indemnify Allergan," alleged Allergan Finance LLC, the subsidiary that filed the lawsuit.

  • Allergan sues Pfizer over costs of opioid litigation
    Reuters13 days ago

    Allergan sues Pfizer over costs of opioid litigation

    In a lawsuit filed in federal court in Cleveland, Ohio, Allergan said the "primary basis" for the claims against it was the alleged improper marketing and sale of Kadian, a form of morphine, in the years before it gained rights to the painkiller in late 2008. "But now that more than a thousand lawsuits seek to impose liability for that very marketing and sale, Pfizer has rejected any responsibility to indemnify Allergan," alleged Allergan Finance LLC, the subsidiary that filed the lawsuit.

  • Allergan Sues Pfizer Over Damages in Opioid Litigation
    Bloomberg13 days ago

    Allergan Sues Pfizer Over Damages in Opioid Litigation

    Allergan Plc sued Pfizer Inc. to cover any potential damages that the drugmaker might be forced to pay as a result of the hundreds of lawsuits it faces over its alleged role in the opioid crisis. Allergan claims the allegations in the opioid litigation involve improper marketing and sale of sale of morphine drug Kadian in the years before it acquired the rights to it. Allergan, then known as Actavis Plc, acquired Kadian in December 2008 from a company that was later acquired by Pfizer.

  • Allergan Sues Pfizer, King Over Opioid Litigation Costs
    Bloomberg13 days ago

    Allergan Sues Pfizer, King Over Opioid Litigation Costs

    Allergan Plc sued Pfizer Inc. to cover potential damages that the drugmaker might be forced to pay stemming from hundreds of lawsuits over its alleged role in the opioid crisis. The suit in federal court ...

  • Eli Lilly: 9% Revenue Growth in Q2 2018 Exceeded Estimates
    Market Realist14 days ago

    Eli Lilly: 9% Revenue Growth in Q2 2018 Exceeded Estimates

    Eli Lilly & Co. (LLY) reported 9.0% growth in its YoY (year-over-year) revenues to ~$6.4 billion during the second quarter, compared to $5.8 billion during the second quarter of 2017. Eli Lilly surpassed Wall Street analysts’ EPS and revenue estimates during the second quarter. On July 24, Eli Lilly reported non-GAAP EPS of $1.50 on revenues of ~$6.4 billion, compared to its estimated EPS of $1.30 on revenues of $6.0 billion during the quarter.